Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma

International Journal of Oncology

Volumn 42, Issue 4, 2013, Pages 1151-1158

  Kato, Hiroaki ^a   Arao, Tokuzo ^a   Matsumoto, Kazuko ^a   Fujita, Yoshihiko ^a   Kimura, Hideharu ^a   Hayashi, Hidetoshi ^a   Nishiki, Kouhei ^a   Iwama, Mitsuru ^a   Shiraishi, Osamu ^a   Yasuda, Atsushi ^a   Shinkai, Masayuki ^a   Imano, Motohiro ^a   Imamoto, Haruhiko ^a   Yasuda, Takushi ^a   Okuno, Kiyotaka ^a   Shiozaki, Hitoshi ^a   Nishio, Kazuto ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

EGFR; Esophageal squamous cell carcinoma; FGFR2; HER2; MET

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; GENOMIC DNA; PARAFFIN; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; DNA ISOLATION; DRUG SENSITIVITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2;

EID: 84874605065     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1830     Document Type: Article

References (29)

1. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y and Kitajima M: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 232:225-232, 2002.
2. Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T and Hatakeyama K: Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg 198:205-211, 2004.
3. Normanno N, De Luca A, Bianco C, et al: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2-16, 2006.
4. Shepard HM, Brdlik CM and Schreiber H: Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 118:3574-3581, 2008.
5. Hanawa M, Suzuki S, Dobashi Y, et al: EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118:1173-1180, 2006.
6. Sunpaweravong P, Sunpaweravong S, Puttawibul P, et al: Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 131:111-119, 2005.
7. Zhan N, Dong WG, Tang YF, Wang ZS and Xiong CL: Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol 29:933-940, 2011.
8. Sato-Kuwabara Y, Neves JI, Fregnani JHTG, Sallum RA and Soares FA: Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using fluorescence in situ hybridization (FISH) and immunohistochemistry. BMC Cancer 9:1207-1471, 2009.
9. Mimura K, Kono K, Hanawa M, et al: Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 92:1253-1260, 2005.
10. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004.
11. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004.
12. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010.
13. Peták I, Schwab R, Orfi L, Kopper L and Kéri G: Integrating molecular diagnostics into anticancer drug discovery. Nat Rev Drug Discov 9:523-535, 2010.
14. Turner N and Grose R: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10:116-129, 2010.
15. Matsumoto K, Arao T, Hamaguchi T, et al: FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 106:727-732, 2012.
16. Takeda M, Arao T, Yokote H, et al: AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 13:3051-3057, 2007.
17. Gherardi E, Birchmeier W, Birchmeier C and Vande Woude G: Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89-103, 2012.
18. Cappuzzo F, Marchetti A, Skokan M, et al: Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27:1667-1674, 2009.
19. Kimura H, Kasahara K, Kawaishi M, et al: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12:3915-3921, 2006.
20. Kaneda H, Arao T, Tanaka K, et al: FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res 70:2053-2063, 2010.
21. Matsumoto K, Arao T, Tanaka K, et al: mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 69:7160-7164, 2009.
22. Kunii K, Davis L, Gorenstein J, et al: FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 68:2340-2348, 2008.
23. Dutt A, Salvesen HB, Chen TH, et al: Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 105:8713-8717, 2008.
24. Lennerz JK, Kwak EL, Ackerman A, et al: MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29:4803-4810, 2011.
25. Okines A, Cunningham D and Chau I: Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 8:492-503, 2011.
26. Kancha RK, Peschel C and Duyster J: The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors. J Thorac Oncol 6:387-392, 2011.
27. Bang YJ, Van Cutsem E, Feyereislova A, et al: ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010.
28. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006.
29. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008.